FIELD: chemistry.
SUBSTANCE: invention relates to salts and crystalline forms of (S)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, wherein the salt is selected from the group consisting of a potassium salt and a meglumine salt, as well as a pharmaceutical composition based on said compounds for the treatment of diseases mediated by a cyclooxygenase-2 inhibitor, a method for preparation and use thereof.
EFFECT: said compounds show good formulation properties such as high aqueous solubility, good intrinsic dissolution, good crystallinity, good thermal stability or low hygroscopicity.
11 cl, 10 dwg, 1 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2012 |
|
RU2630617C2 |
| CRYSTAL AND SALT FORMS OF PPAR AGONIST COMPOUNDS | 2017 |
|
RU2759724C2 |
| PHARMACEUTICALLY ACCEPTABLE THYMODEPRESSIN SALTS AND METHOD OF OBTAINING THEREOF | 2007 |
|
RU2536685C2 |
| METHOD FORASYMMETRICTRANSFORMATION OF SUBSTITUTED 2H-CHROMENE-3-CARBOXY ACIDS DUE TO DIFFERENTIAL SOLUBILITY | 2020 |
|
RU2792894C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| NOVEL SOLID FORMS (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CARBOXYLIC ACID | 2020 |
|
RU2820501C2 |
| ADDITION SALT OF THE S1P1 RECEPTOR AGONIST AND ITS CRYSTALLINE FORM AND PHARMACEUTICAL COMPOSITION BASED ON IT | 2018 |
|
RU2822288C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| 1-[(4-[BENZOYL(METHYL)AMINO]-3-(PHENYL)BUTYL] AZETIDINE DERIVATIVES FOR TREATMENT OF GASTROINTESTINAL DISORDERS | 2007 |
|
RU2439067C2 |
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
